Supplier
Wetzel County Hospital, INC.
Wetzel County Hospital, INC. was paid $2.54M by Medicaid between Jul 2020 and Dec 2024, across 123 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.
33Billing provider infoWETZEL COUNTY HOSPITAL, INC.
NEW MARTINSVILLE, WV 26155
NEW MARTINSVILLE, WV 26155
33aNPI1376175240assigned 02/10/2020
33bProvider typeInstitutional Pharmacy
28Total paid$2.54M
24GClaims115,503
24DCodes billed123
24AFirst – last monthJul 2020 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 12,022 | $278K | |
| 2021 | 24,408 | $617K | |
| 2022 | 17,649 | $515K | |
| 2023 | 33,360 | $570K | |
| 2024incomplete | 28,064 | $556K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 4,552 | 3,950 | $555K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 21% | 2,282 | 1,934 | $536K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 6,580 | 5,796 | $506K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 5.9% | 2,207 | 1,956 | $151K |
| 80053 | Comprehensive metabolic panel | 2.7% | 10,560 | 9,013 | $68K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 606 | 533 | $57K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.9% | 4,537 | 4,175 | $48K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 11,075 | 9,164 | $47K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 1,030 | 923 | $46K |
| 80061 | Lipid panel | 1.6% | 4,462 | 4,140 | $42K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.5% | 1,546 | 415 | $37K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 1,110 | 833 | $35K |
111 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 794 | $32K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 577 | $24K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,132 | $22K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,011 | $20K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 321 | $19K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,882 | $19K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 421 | $15K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 243 | $14K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,611 | $13K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 700 | $12K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,734 | $11K |
| 84484 | <1% | 2,304 | $10K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,032 | $9K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,419 | $9K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 46 | $9K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 862 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,250 | $8K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,779 | $8K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 965 | $7K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 329 | $7K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 425 | $7K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 318 | $7K |
| 83605 | <1% | 1,694 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,449 | $6K |
| 85027 | <1% | 1,626 | $6K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 187 | $6K |
| 83880 | <1% | 616 | $5K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,007 | $5K |
| 83735 | <1% | 1,695 | $5K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 77 | $4K |
| 87186 | <1% | 863 | $4K | |
| 87077 | <1% | 884 | $4K | |
| 83690 | <1% | 1,513 | $4K | |
| 85610 | <1% | 1,907 | $4K | |
| 82607 | <1% | 346 | $3K | |
| 81003 | <1% | 2,467 | $3K | |
| 82248 | <1% | 1,538 | $3K | |
| 87040 | <1% | 492 | $3K | |
| 81001 | <1% | 1,656 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 413 | $2K |
| 81025 | <1% | 322 | $2K | |
| 80050 | General health panel | <1% | 55 | $2K |
| 82803 | <1% | 311 | $2K | |
| 82550 | <1% | 769 | $2K | |
| 87081 | <1% | 563 | $2K | |
| 73630 | <1% | 156 | $2K | |
| 97161 | <1% | 30 | $2K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 28 | $1K |
| 85379 | <1% | 231 | $1K | |
| 73610 | <1% | 88 | $1K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 22 | $1K |
| 82043 | <1% | 323 | $1K | |
| 87088 | <1% | 180 | $1K | |
| 86140 | <1% | 401 | $1K | |
| 90746 | <1% | 14 | $1K | |
| 82570 | <1% | 252 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 715 | $950.52 |
| Q3014 | Telehealth originating site facility fee | <1% | 45 | $942.59 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 51 | $896.51 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 65 | $886.04 |
| 90656 | <1% | 67 | $748.80 | |
| 83540 | <1% | 187 | $737.29 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 30 | $727.30 |
| 84466 | <1% | 132 | $662.50 | |
| 84439 | <1% | 84 | $658.91 | |
| 86803 | <1% | 79 | $650.62 | |
| 82728 | <1% | 91 | $570.16 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 99 | $537.86 |
| 96376 | <1% | 56 | $519.28 | |
| 73030 | <1% | 59 | $485.58 | |
| 85007 | <1% | 147 | $458.37 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,347 | $431.12 |
| 84703 | <1% | 117 | $417.20 | |
| 72110 | <1% | 28 | $405.06 | |
| 80306 | <1% | 55 | $396.72 | |
| 84100 | <1% | 167 | $358.82 | |
| 90686 | <1% | 43 | $351.82 | |
| 84460 | <1% | 84 | $334.12 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 20 | $332.08 |
| 82962 | <1% | 276 | $317.13 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12 | $276.12 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 14 | $270.87 |
| 90715 | <1% | 16 | $238.30 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 15 | $235.58 |
| 85652 | <1% | 173 | $234.01 | |
| 84450 | <1% | 63 | $222.30 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 13 | $216.78 |
| 84153 | <1% | 16 | $190.16 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 78 | $183.49 |
| 73560 | <1% | 18 | $179.64 | |
| 73562 | <1% | 32 | $173.66 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 135 | $172.92 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,081 | $170.01 |
| 87807 | <1% | 13 | $160.24 | |
| 74018 | <1% | 12 | $147.68 | |
| 80076 | <1% | 16 | $111.78 | |
| 82948 | <1% | 16 | $90.14 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 129 | $83.02 |
| 82746 | <1% | 14 | $82.02 | |
| C1755 | Catheter, intraspinal | <1% | 14 | $69.80 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 65 | $62.63 |
| 96367 | <1% | 18 | $61.82 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 94 | $58.07 |
| 85730 | <1% | 14 | $50.26 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 18 | $46.46 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 34 | $31.71 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 13 | $5.28 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 44 | $4.68 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 63 | $1.00 |
| J3490 | Unclassified drugs | 0% | 1,326 | $0.00 |
| G0475 | Hiv antigen/antibody, combination assay, screening | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHESS, DAVID (PRESIDENT & CEO)
| Provider | Location | Paid |
|---|---|---|
| Reynolds Memorial Hospital, INC | Glen Dale, WV | $11.45M |
| Fayette Physician Network INC | Friendsville, MD | $3.33M |
| Wetzel County Hospital, INC. | New Martinsville, WV | $2.04M |
| Wetzel County Hospital, INC. | New Martinsville, WV | $915K |
| Wetzel County Hospital, INC. | New Martinsville, WV | $321K |
| Cgi Anesthesia Associates LLC | Cincinnati, OH | $36K |
| David E Hess M.D., INC. | Bridgeport, WV | $35K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.